In , Sudarshan Pharma Industries Ltd (Trading) is outperforming Nifty 500 with +20.8% relative strength. Fundamentals: Average. On a 5-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Apr 18, 2026
What: PLI Scheme Approval: ₹115 Cr Total Incentive
Impact: High
“The company has received approval under the Production Linked Incentive (PLI) scheme... Maximum Total Incentive ₹115 Crore.”
What: Export Revenue %: 15%
Impact: ₹131 Cr Revenue
“We are targeting Whole African Sectors, MENA Region, Gulf Countries... Our Target For FY 25-26: Min:100 CR.”
What: EBITDA Margin: 13.5%
Impact: 510 bps expansion
“EBIDTA % to Revenue is projected to reach 13.5% in FY25-26 as manufacturing capabilities increase.”
What: Oncology API Portfolio: 7 Products
“Oncology API’s: Gemcitabine, T9, Apalutamide, Olaparib, Crizotinib, Cisplatin, Lenalidomide.”
What: Novel Drug Delivery System: 5 Products
“SPIL has introduced a novel drug delivery system under the Love Bird Brand, featuring a mouth-dissolving strip.”
What: Sequential PAT growth of 7.2%
“The Company is continuously focusing on increase in exports and manufacturing sales... consequently, the Company has achieved substantial growth in PAT.”
What: 8.4% → 13.5%
“EBIDTA % to Revenue projected at 13.5% for FY25-26 compared to 8.4% in FY24-25.”
Earnings deceleration risks from management commentary
Trigger: India imports ~70% of intermediates required for APIs from China, making it vulnerable to supply disruptions.
Management view: Setting up own manufacturing units to produce critical APIs currently imported from China.
Monitor: geopolitical
Trigger: Price rises for key APIs and intermediates due to environmental shutdowns in China.
Management view: Focusing on backward integration and local sourcing to mitigate price shocks.
Monitor: commodity
Trigger: Entering regulated markets requires stringent adherence to quality and documentation norms.
Management view: Acquiring a plant that already has USFDA and WHO approvals.
Monitor: regulatory
Key quotes from recent conference calls
“We are targeting Whole African Sectors, MENA Region, Gulf Countries... Our Target For FY 25-26: Min:100 CR [Previous Revenue Target FY26 guidance]”
“Planned Strategic Acquisition Manufacturing unit In India... USFDA Plant INR:200cr +50cr =250cr. [Initiative: USFDA Plant Acquisition]”
“Proposed fund raising of FCCB of USD 35 Million for the period 2025-2026. [Initiative: FCCB Fund Raising]”
“India imports ~70% of Intermediate required for APIs from China... Sudarshan Pharma is setting up a manufacturing unit to manufacture few of the critical APIs. [Risk (geopolitical): HIGH]”
Headline numbers from the latest earnings call
Revenue
₹168.0 Cr
Why: Revenue remained relatively flat on a sequential basis as the company focused on margin optimization over pure volume growth in local API resale markets.
The company maintained steady revenue despite a slight sequential dip, prioritizing higher-margin manufacturing sales.
EBITDA
₹6.1 Cr
Why: EBITDA was impacted by higher cost of materials consumed which rose to 13.21 Crores during the quarter.
Margins are under pressure due to a sharp increase in raw material consumption costs during the current quarter.
PAT
₹4.2 Cr
Why: PAT growth was supported by a reduction in purchase of stock-in-trade and controlled other expenses.
Despite higher material costs, PAT improved sequentially due to better operational efficiencies and lower trading purchases.
Other Highlights
• Basic EPS for the quarter stood at 0.18 per share.
• Total Income for the quarter reached 169.52 Crores.
• Purchase of stock-in-trade reduced to 148.81 Crores from 171.18 Crores QoQ.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
USFDA Plant Status
Approved
Why: The company is in the process of acquiring a facility that already holds USFDA and WHO approvals.
Export Revenue % of Total
15%
Why: Strategic focus on expanding the sales footprint in international markets like Africa and MENA.
Total PLI Incentive
₹115 Cr
Why: Approval received for Vitamin B1 and B6 manufacturing projects.
Oncology API Portfolio
7 Products
Why: Expansion into high-value specialty therapeutic segments.
Palghar Unit Capacity
6,000 Litres
Why: Scalable production output across two shifts at the oral liquid section.
Growth Funds - Capex
₹38.65 Cr
Why: Significant investment in R&D and new manufacturing technology like Flow Reactors.
Inventory Holding Days
101 Days
Why: Increased inventory levels to support the ramp-up in manufacturing and export sales.
Debt to Equity Ratio
1.4x
Why: Higher borrowing to fund the aggressive acquisition and expansion strategy.
Forward-looking targets from management for FY26
OPM Guidance
13.5%
Capex Plan
₹302.15 Cr
₹877.65 Cr
RAISED
₹302.15 Cr
Strategic acquisitions of manufacturing units in India and growth funds for capacity expansion.
Guidance Changes
EBITDA Margin: 8.4% → 13.5%
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +36% | +15% | Stable |
| PAT (Net Profit) | +57% | +49% | Stable |
| OPM | 9.0% | -100 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Sudarshan Pharma Industries Ltd's latest quarterly results (Mar 2026) show
Sudarshan Pharma Industries Ltd's profit is growing with an stable trend.
Sudarshan Pharma Industries Ltd's revenue growth trend is stable.
Sudarshan Pharma Industries Ltd's operating margin is volatile.
Sudarshan Pharma Industries Ltd's long-term compounding rates
Sudarshan Pharma Industries Ltd's earnings growth is stable with mixed signals on a sequential basis.
Sudarshan Pharma Industries Ltd's trailing twelve month (TTM) performance
Sudarshan Pharma Industries Ltd appears significantly overvalued based on our fair value analysis.
Sudarshan Pharma Industries Ltd's current PE ratio is 31.3x.
Sudarshan Pharma Industries Ltd's current PE is 31.3x.
Sudarshan Pharma Industries Ltd's price-to-book ratio is 4.7x.
Sudarshan Pharma Industries Ltd is rated Average with a fundamental score of 41/100. This score is calculated from objective financial metrics
Sudarshan Pharma Industries Ltd has a debt-to-equity ratio of N/A.
Sudarshan Pharma Industries Ltd's return ratios over recent years
Sudarshan Pharma Industries Ltd's operating cash flow is negative (FY2026).
Sudarshan Pharma Industries Ltd currently does not pay a significant dividend (yield 0.00%).
Sudarshan Pharma Industries Ltd's shareholding pattern (Mar 2026)
Sudarshan Pharma Industries Ltd's promoter holding has remained stable recently.
Sudarshan Pharma Industries Ltd has been outperforming Nifty 500 for 5 consecutive weeks, indicating building momentum.
Sudarshan Pharma Industries Ltd is an established outperformer with 5 weeks of consecutive Nifty 500 outperformance.
Sudarshan Pharma Industries Ltd has 7 key growth catalysts identified from recent earnings analysis
Sudarshan Pharma Industries Ltd has 3 key risks worth monitoring
In Q3 FY26, Sudarshan Pharma Industries Ltd's management highlighted
Sudarshan Pharma Industries Ltd's management has provided the following forward guidance for FY26
Sudarshan Pharma Industries Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Sudarshan Pharma Industries Ltd may be worth studying
Sudarshan Pharma Industries Ltd investment thesis summary:
Sudarshan Pharma Industries Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
